Constipation News and Research

Latest Constipation News and Research

Low-gluten beers can cause symptoms in patients with celiac disease

Beer tested in a new study, including some brands labeled "low-gluten," contains levels of hordein, the form of gluten present in barley, that could cause symptoms in patients with celiac disease (CD), the autoimmune condition treated with a life-long gluten-free diet, scientists are reporting.

22 Dec 2011

Diseases of the Colon & Rectum publishes results from Pacira's EXPAREL Phase 3 trial

Pacira Pharmaceuticals, Inc. today announced the publication of data from a placebo-controlled, pivotal Phase 3 trial of EXPAREL (bupivacaine liposome injectable suspension), a non-opioid local analgesic that was recently approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.

19 Dec 2011

Simple online calculator can tackle pancreatic and bowel cancer

A simple online calculator could offer family GPs a powerful new tool in tackling two of the most deadly forms of cancer, say researchers.

15 Dec 2011

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

Nektar Therapeutics today announced positive data from a Phase 1 clinical study of NKTR-181 evaluating multiple ascending oral doses of NKTR-181 over an 8-day treatment period in healthy subjects.

14 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

VIVUS announces results of Qnexa clinical study on cardiometabolic disease

VIVUS, Inc. today announced that results from the SEQUEL study were published in The American Journal of Clinical Nutrition, a peer-reviewed journal with broad, multidisciplinary readership.

9 Dec 2011

Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

Pfizer Inc. announced today the top-line primary endpoint result for Toviaz (fesoterodine fumarate) Study A0221049 - Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder.

6 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

Dramatic nationwide rise in opioid use for chronic abdominal pain

Across U.S. outpatient clinics between 1997 and 2008, opioid prescriptions for chronic abdominal pain more than doubled, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

30 Nov 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

Psychological problems can influence patient's viewpoint of IBS symptom severity

A patient's viewpoint of the severity of irritable bowel syndrome (IBS) symptoms can be influenced not only by physical symptoms of IBS but broader psychological problems, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

22 Nov 2011

FDA approves Abbott's new Chagas in vitro diagnostic test

Abbott received approval from the U.S. Food and Drug Administration (FDA) for a new Chagas in vitro diagnostic test.

21 Nov 2011

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.

21 Nov 2011

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Genentech, a member of the Roche Group, announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.

18 Nov 2011

EC approves Pfizer's Vyndaqel to treat Transthyretin Familial Amyloid Polyneuropathy

Pfizer announced today that the European Commission has approved Vyndaqel (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy.

17 Nov 2011

New possibilities for relief from digestive diseases

As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.

17 Nov 2011

Fiber from whole grains reduces risk of bowel cancer: Study

The researchers from Britain and the Netherlands found that the more total dietary fiber and cereal fiber people consumed, the lower their colorectal cancer risk. For example, people who consumed an extra 90 grams of fiber from whole grains a day also had a 20 percent lower risk of colorectal cancer, according to the British Medical Journal review.

14 Nov 2011

Constipation News and Research

Latest Constipation News and Research

Low-gluten beers can cause symptoms in patients with celiac disease

Diseases of the Colon & Rectum publishes results from Pacira's EXPAREL Phase 3 trial

Simple online calculator can tackle pancreatic and bowel cancer

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene announces interim results of REVLIMID study on CLL

VIVUS announces results of Qnexa clinical study on cardiometabolic disease

Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Dramatic nationwide rise in opioid use for chronic abdominal pain

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Psychological problems can influence patient's viewpoint of IBS symptom severity

FDA approves Abbott's new Chagas in vitro diagnostic test

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

EC approves Pfizer's Vyndaqel to treat Transthyretin Familial Amyloid Polyneuropathy

New possibilities for relief from digestive diseases

Fiber from whole grains reduces risk of bowel cancer: Study

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Constipation News and Research

Latest Constipation News and Research

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Newsletters you may be interested in